203 related articles for article (PubMed ID: 14699428)
1. Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression.
Alonso R; Griebel G; Pavone G; Stemmelin J; Le Fur G; Soubrié P
Mol Psychiatry; 2004 Mar; 9(3):278-86, 224. PubMed ID: 14699428
[TBL] [Abstract][Full Text] [Related]
2. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal.
Surget A; Saxe M; Leman S; Ibarguen-Vargas Y; Chalon S; Griebel G; Hen R; Belzung C
Biol Psychiatry; 2008 Aug; 64(4):293-301. PubMed ID: 18406399
[TBL] [Abstract][Full Text] [Related]
3. Involvement of vasopressin 3 receptors in chronic psychological stress-induced visceral hyperalgesia in rats.
Bradesi S; Martinez V; Lao L; Larsson H; Mayer EA
Am J Physiol Gastrointest Liver Physiol; 2009 Feb; 296(2):G302-9. PubMed ID: 19033533
[TBL] [Abstract][Full Text] [Related]
4. The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice.
Urani A; Philbert J; Cohen C; Griebel G
Pharmacol Biochem Behav; 2011 May; 98(3):425-31. PubMed ID: 21356230
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression.
Hodgson RA; Higgins GA; Guthrie DH; Lu SX; Pond AJ; Mullins DE; Guzzi MF; Parker EM; Varty GB
Pharmacol Biochem Behav; 2007 Mar; 86(3):431-40. PubMed ID: 17291571
[TBL] [Abstract][Full Text] [Related]
6. An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model.
Iijima M; Chaki S
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):622-7. PubMed ID: 17229509
[TBL] [Abstract][Full Text] [Related]
7. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
Griebel G; Simiand J; Serradeil-Le Gal C; Wagnon J; Pascal M; Scatton B; Maffrand JP; Soubrie P
Proc Natl Acad Sci U S A; 2002 Apr; 99(9):6370-5. PubMed ID: 11959912
[TBL] [Abstract][Full Text] [Related]
8. Suppression of adrenocorticotrophic hormone secretion by simultaneous antagonism of vasopressin 1b and CRH-1 receptors on three different stress models.
Ramos AT; Troncone LR; Tufik S
Neuroendocrinology; 2006; 84(5):309-16. PubMed ID: 17135717
[TBL] [Abstract][Full Text] [Related]
9. An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders.
Serradeil-Le Gal C; Wagnon J; Tonnerre B; Roux R; Garcia G; Griebel G; Aulombard A
CNS Drug Rev; 2005; 11(1):53-68. PubMed ID: 15867952
[TBL] [Abstract][Full Text] [Related]
10. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression.
Goshen I; Kreisel T; Ben-Menachem-Zidon O; Licht T; Weidenfeld J; Ben-Hur T; Yirmiya R
Mol Psychiatry; 2008 Jul; 13(7):717-28. PubMed ID: 17700577
[TBL] [Abstract][Full Text] [Related]
11. Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat.
Overstreet DH; Griebel G
Pharmacol Biochem Behav; 2005 Sep; 82(1):223-7. PubMed ID: 16181667
[TBL] [Abstract][Full Text] [Related]
12. Chronic stress-induced alterations in amygdala responsiveness and behavior--modulation by trait anxiety and corticotropin-releasing factor systems.
Sandi C; Cordero MI; Ugolini A; Varea E; Caberlotto L; Large CH
Eur J Neurosci; 2008 Nov; 28(9):1836-48. PubMed ID: 18973598
[TBL] [Abstract][Full Text] [Related]
13. I.c.v. administration of orexin-A induces an antidepressive-like effect through hippocampal cell proliferation.
Ito N; Yabe T; Gamo Y; Nagai T; Oikawa T; Yamada H; Hanawa T
Neuroscience; 2008 Dec; 157(4):720-32. PubMed ID: 18952152
[TBL] [Abstract][Full Text] [Related]
14. Hippocampal neurogenesis and behavioural studies on adult ischemic rat response to chronic mild stress.
Wang SH; Zhang ZJ; Guo YJ; Teng GJ; Chen BA
Behav Brain Res; 2008 May; 189(1):9-16. PubMed ID: 18258314
[TBL] [Abstract][Full Text] [Related]
15. Nelumbinis Semen reverses a decrease in 5-HT1A receptor binding induced by chronic mild stress, a depression-like symptom.
Jang CG; Kang M; Cho JH; Lee SB; Kim H; Park S; Lee J; Park SK; Hong M; Shin MK; Shim IS; Bae H
Arch Pharm Res; 2004 Oct; 27(10):1065-72. PubMed ID: 15554266
[TBL] [Abstract][Full Text] [Related]
16. Gonadotropin-releasing hormone agonist blocks anxiogenic-like and depressant-like effect of corticotrophin-releasing hormone in mice.
Umathe SN; Bhutada PS; Jain NS; Shukla NR; Mundhada YR; Dixit PV
Neuropeptides; 2008 Aug; 42(4):399-410. PubMed ID: 18533256
[TBL] [Abstract][Full Text] [Related]
17. Differential role of corticotrophin-releasing factor receptor types 1 and 2 in stress-induced suppression of pulsatile luteinising hormone secretion in the female rat.
Li XF; Bowe JE; Kinsey-Jones JS; Brain SD; Lightman SL; O'Byrne KT
J Neuroendocrinol; 2006 Aug; 18(8):602-10. PubMed ID: 16867181
[TBL] [Abstract][Full Text] [Related]
18. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?
Nielsen DM
Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764
[TBL] [Abstract][Full Text] [Related]
19. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders.
Griebel G; Simiand J; Steinberg R; Jung M; Gully D; Roger P; Geslin M; Scatton B; Maffrand JP; Soubrié P
J Pharmacol Exp Ther; 2002 Apr; 301(1):333-45. PubMed ID: 11907191
[TBL] [Abstract][Full Text] [Related]
20. Blockade of central vasopressin receptors reduces the cardiovascular response to acute stress in freely moving rats.
Stojicić S; Milutinović-Smiljanić S; Sarenac O; Milosavljević S; Paton JF; Murphy D; Japundzić-Zigon N
Neuropharmacology; 2008 Apr; 54(5):824-36. PubMed ID: 18339407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
